611 related articles for article (PubMed ID: 8244583)
21. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity.
Liebmann JE; Hahn SM; Cook JA; Lipschultz C; Mitchell JB; Kaufman DC
Cancer Res; 1993 May; 53(9):2066-70. PubMed ID: 8097674
[TBL] [Abstract][Full Text] [Related]
22. Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion.
Andrews PA; Schiefer MA; Murphy MP; Howell SB
Chem Biol Interact; 1988; 65(1):51-8. PubMed ID: 3345573
[TBL] [Abstract][Full Text] [Related]
23. Role of glutathione in the in vitro synergism between 4-hydroperoxy-cyclophosphamide and cisplatin in leukemia cell lines.
Peters RH; Jollow DJ; Stuart RK
Cancer Res; 1991 May; 51(10):2536-41. PubMed ID: 2021933
[TBL] [Abstract][Full Text] [Related]
24. Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells.
Ali-Osman F; Antoun G; Wang H; Rajagopal S; Gagucas E
Mol Pharmacol; 1996 Jun; 49(6):1012-20. PubMed ID: 8649339
[TBL] [Abstract][Full Text] [Related]
25. Effects of glutathione depletion by buthionine sulfoximine on the sensitivity of EMT6/SF cells to chemotherapy agents or X radiation.
Shrieve DC; Harris JW
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1171-4. PubMed ID: 3744936
[TBL] [Abstract][Full Text] [Related]
26. Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines.
Lai GM; Ozols RF; Young RC; Hamilton TC
J Natl Cancer Inst; 1989 Apr; 81(7):535-9. PubMed ID: 2493524
[TBL] [Abstract][Full Text] [Related]
27. Schedule dependence of buthionine sulfoximine in reversing resistance to cisplatin.
Robichaud NJ; Fram RJ
Chem Biol Interact; 1990; 76(3):333-42. PubMed ID: 2225234
[TBL] [Abstract][Full Text] [Related]
28. Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells.
Chen G; Waxman DJ
Biochem Pharmacol; 1994 Mar; 47(6):1079-87. PubMed ID: 8147907
[TBL] [Abstract][Full Text] [Related]
29. Effect of buthionine sulfoximine and ethacrynic acid on cytotoxic activity of mitomycin C analogues BMY 25282 and BMY 25067.
Xu BH; Singh SV
Cancer Res; 1992 Dec; 52(23):6666-70. PubMed ID: 1423311
[TBL] [Abstract][Full Text] [Related]
30. Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion.
Andrews PA; Murphy MP; Howell SB
Cancer Res; 1985 Dec; 45(12 Pt 1):6250-3. PubMed ID: 4063975
[TBL] [Abstract][Full Text] [Related]
31. Buthionine sulfoximine enhances glutathione-but attenuates glutamate-stimulated cell proliferation.
Kang YJ
Cell Mol Biol Res; 1995; 41(2):131-6. PubMed ID: 8581064
[TBL] [Abstract][Full Text] [Related]
32. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
Kisara S; Furusawa S; Murata R; Ogata M; Hikichi N; Takayanagi Y; Sasaki K
Oncol Res; 1995; 7(3-4):191-200. PubMed ID: 8555653
[TBL] [Abstract][Full Text] [Related]
33. Differential sensitivities of murine melanocytes and melanoma cells to buthionine sulfoximine and anticancer drugs.
Thrall BD; Raha GA; Springer DL; Meadows GG
Pigment Cell Res; 1991 Dec; 4(5-6):234-9. PubMed ID: 1823927
[TBL] [Abstract][Full Text] [Related]
34. The role of platinum uptake and glutathione levels in L1210 cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.
Nicolson MC; Orr RM; O'Neill CF; Harrap KR
Neoplasma; 1992; 39(3):189-95. PubMed ID: 1528325
[TBL] [Abstract][Full Text] [Related]
35. Sensitivity of human melanoma cells to L-dopa and DL-buthionine (S,R)-sulfoximine.
Kable EP; Favier D; Parsons PG
Cancer Res; 1989 May; 49(9):2327-31. PubMed ID: 2706620
[TBL] [Abstract][Full Text] [Related]
36. Nitrogen mustard-DNA interaction in melphalan-resistant mammary carcinoma cells with elevated intracellular glutathione and glutathione-S-transferase activity.
Alaoui-Jamali MA; Panasci L; Centurioni GM; Schecter R; Lehnert S; Batist G
Cancer Chemother Pharmacol; 1992; 30(5):341-7. PubMed ID: 1505071
[TBL] [Abstract][Full Text] [Related]
37. [Increasing chemosensitivity to cisplatin by glutathione depletion with buthionine sulfoximine. In vitro and in vivo studies with a human squamous cell cancer line].
Bier H
Laryngorhinootologie; 1990 Jan; 69(1):16-20. PubMed ID: 2310456
[TBL] [Abstract][Full Text] [Related]
38. Glutathione depletion by DL-buthionine-SR-sulfoximine (BSO) potentiates X-ray-induced chromosome lesions after liquid holding recovery.
Bertsche U; Schorn H
Radiat Res; 1986 Mar; 105(3):351-69. PubMed ID: 3754339
[TBL] [Abstract][Full Text] [Related]
39. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
Lai SL; Hwang J; Perng RP; Whang-Peng J
Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042
[TBL] [Abstract][Full Text] [Related]
40. Buthionine sulfoximine spares intracellular glutamate: a possible mechanism for cell growth stimulation.
Kang YJ
Cell Mol Biol Res; 1993; 39(7):675-84. PubMed ID: 8055000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]